BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22840368)

  • 1. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
    Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
    Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
    Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
    Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.
    Inamura K; Yamauchi M; Nishihara R; Kim SA; Mima K; Sukawa Y; Li T; Yasunari M; Zhang X; Wu K; Meyerhardt JA; Fuchs CS; Harris CC; Qian ZR; Ogino S
    Ann Surg Oncol; 2015 Apr; 22(4):1226-1235. PubMed ID: 25326395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
    Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
    Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
    Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
    Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.
    Morikawa T; Kuchiba A; Liao X; Imamura Y; Yamauchi M; Qian ZR; Nishihara R; Sato K; Meyerhardt JA; Fuchs CS; Ogino S
    Int J Cancer; 2012 Sep; 131(5):1169-78. PubMed ID: 22038927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
    Firestein R; Shima K; Nosho K; Irahara N; Baba Y; Bojarski E; Giovannucci EL; Hahn WC; Fuchs CS; Ogino S
    Int J Cancer; 2010 Jun; 126(12):2863-73. PubMed ID: 19790197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.
    Yamauchi M; Morikawa T; Kuchiba A; Imamura Y; Qian ZR; Nishihara R; Liao X; Waldron L; Hoshida Y; Huttenhower C; Chan AT; Giovannucci E; Fuchs C; Ogino S
    Gut; 2012 Jun; 61(6):847-54. PubMed ID: 22427238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
    Mima K; Nowak JA; Qian ZR; Cao Y; Song M; Masugi Y; Shi Y; da Silva A; Gu M; Li W; Hamada T; Zhang X; Wu K; Meyerhardt JA; Baba H; Giovannucci EL; Chan AT; Fuchs CS; Ogino S; Nishihara R
    Oncotarget; 2016 Aug; 7(34):55098-55109. PubMed ID: 27391152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.
    Morikawa T; Kuchiba A; Qian ZR; Mino-Kenudson M; Hornick JL; Yamauchi M; Imamura Y; Liao X; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
    Ann Surg Oncol; 2012 Jun; 19(6):1944-53. PubMed ID: 22189472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
    Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
    World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.
    Li T; Liao X; Lochhead P; Morikawa T; Yamauchi M; Nishihara R; Inamura K; Kim SA; Mima K; Sukawa Y; Kuchiba A; Imamura Y; Baba Y; Shima K; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S; Qian ZR
    Ann Surg Oncol; 2014 Dec; 21(13):4164-73. PubMed ID: 25023548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
    Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.